Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Hepatocellular 18Colorectal Neoplasms 17Stomach Neoplasms 12Esophageal Squamous Cell Carcinoma 10Neoplasm Metastasis 9Advanced Solid Tumor 9Squamous Cell Carcinoma of Head and Neck 7Lung Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 5Small Cell Lung Carcinoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Esophageal Neoplasms 4Solid Tumor 3Lymphoma, Follicular 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 35Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 23Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Docetaxel 19Oxaliplatin 18Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Ipilimumab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms × tislelizumab × 1 year × Clear all
NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
98 enrolled
Tumor-Agnostic

Neoplasms

NCT04363801 2025-10-09

DisTinGuish

Leap Therapeutics, Inc.

Phase 2 Terminated
247 enrolled 38 charts
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

BeiGene

Phase 1/2 Completed
53 enrolled 17 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡